Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Therapies after progression on PD-1 inhibitor and platinum

12 evidence topics · 12 sources

OrigAMI-4: efficacy results
OutcomeRYBREVANT FASPRO (N=102)
Overall response rate (95% CI)“42% (32%, 52%)”
Complete response“15%”
Partial response“28%”
Duration of response, range (months)“1.4+, 19.7+”
Patients with duration of response of 6 months or longer“56%”